Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $22.80, for a total value of $342,000.00. Following the transaction, the insider directly owned 394,786 shares in the company, valued at $9,001,120.80. This trade represents a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total transaction of $398,850.00.

Kestra Medical Technologies Price Performance

Shares of KMTS opened at $22.85 on Tuesday. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $25.63 and its 200 day simple moving average is $22.16. The company has a market cap of $1.33 billion and a price-to-earnings ratio of -7.21. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on KMTS. BTIG Research assumed coverage on Kestra Medical Technologies in a research report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price objective for the company. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Piper Sandler lifted their price objective on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. Finally, The Goldman Sachs Group set a $24.00 target price on shares of Kestra Medical Technologies in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of KMTS. China Universal Asset Management Co. Ltd. acquired a new position in shares of Kestra Medical Technologies in the third quarter valued at about $48,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Kestra Medical Technologies during the 2nd quarter worth approximately $54,000. BNP Paribas Financial Markets increased its holdings in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period. Brown Brothers Harriman & Co. raised its position in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Kestra Medical Technologies in the second quarter valued at approximately $93,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.